Skip to main
RNXT
RNXT logo

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx Inc. has demonstrated a notable increase in revenue, reporting $422K in Q2, a substantial rise from $197K in Q1. The company anticipates continued growth, projecting revenues to reach approximately $1.3 million in 2025 and $4.5 million in 2026, reflecting the potential demand for its innovative therapy platform. As a clinical-stage biopharmaceutical firm, RenovoRx is positioned to significantly enhance its financial performance as its proprietary treatments advance in development and market adoption increases.

Bears say

RenovoRx Inc. is facing significant challenges, as evidenced by a reported revenue of $0.4 million against a net loss of $2.9 million, which translates to an earnings per share (EPS) of $(0.08). The company's product development is focused on treating pancreatic cancer, one of the deadliest cancers with a dismal 5-year survival rate of just 12%, highlighting the high unmet medical need but also significant market risk. Despite some potential growth prospects, the current financial losses and the harsh realities of the oncology market contribute to a negative outlook on the company's stock.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.